377P - Overall prognosis of advanced breast cancer (ABC) according to chemotherapy (CT) treatment lines: correlation analysis between progression-free-, p...
Date | 27 September 2014 |
Event | ESMO 2014 |
Session | Poster Display session |
Topics | Anticancer Agents Breast Cancer Therapy Biological Therapy |
Presenter | Rosachiara Forcignano` |
Citation | Annals of Oncology (2014) 25 (suppl_4): iv116-iv136. 10.1093/annonc/mdu329 |
Authors |
R. Forcignano`1, E. Bria2, A. Fabi3, L. Petrucelli1, J. Furlanetto4, L. Carbognin4, A. Gambino1, C. Vicentini2, V. Saracino1, L. Lupo1, V.E. Chiuri1, G. Cairo1, G. Tortora5, E. De Matteis1, G. Ronzino6, A. Tornesello1, I. Sperduti7, D. Giannarelli7, M. Ciccarese8
|
Abstract
Aim
ABC remains an incurable disease although the introduction of targeted agents and newest drugs has significantly improved the overall outcome. Nevertheless, the degree of the benefit provided by CT beyond the 3rd line is controversial.
Methods
Data of consecutive ABC patients (pts) were retrospectively gathered, according to pathological subtype (Ki67 < 20%: Luminal A, Luminal B: Ki67 ≥ 20%; HER2-positive, and triple negative) and clinical factors. The hazard ratio (HR) and the 95% confidence intervals (95% CI) were estimated using the Cox uni- and multivariate proportional model. The log-rank analysis for PFS, PPS and OS was used; the correlation between outcomes was performed as well.
Results
The characteristics of 485 pts from 3 different institutions were: median age: 60 years (29-91); median time from primary: 29 months (0-721), median number of sites: 2 (1-6); visceral/bone only disease: 300 (62%)/125 (26%); Luminal A/B/HER2-positive/triple-negative/non-evaluable: 92 (19%)/124 (25%)/117 (24%)/41 (9%)/111 (23%); median number of CT lines: 2 (1-12); overall OS: 45 months (95% CI 34-56). Age (HR 1.01, 95% CI 1.01-1.03, p = 0.04), <2 metastatic sites (HR 1.58, 95% CI 1.14-2.21, p = 0.01), low Ki67 (HR 1.62, 95% CI 1.14-2.29, p = 0.01), and treatment with hormonal therapy (HR 2.06, 95% CI 1.49-2.87, p < 0.01) were independent predictors of longer OS at the multivariate analysis. Median OS according for subtypes was: Luminal A 48 months (95% CI 34-56), Luminal B 37 (95% CI: 28-42), HER2-positive 39 (95% CI 30-44), and triple-negative 15 (95% CI: 11-29). Patients receiving ≥3 CT lines fared significantly better than those undergone <3 lines (50 months [95% CI 46-55] vs 29 [95% CI 31-39], p < 0.0001). Both PFS and PPS were significantly correlated with OS from 1st to 6th line (p < 0.0001), with a trend from 7th to 8th (PFS: p = 0.45 and p = 0.03; PPS: p = 0.003 and p = 0.07, respectively).
Conclusions
These data suggest that CT beyond 3rd line may potentially have a significant impact upon survival. The correlation between OS and both PPS and PFS is consistently maintained across all treatment lines.
Disclosure
All authors have declared no conflicts of interest.